Article information
Atazanavir es un fármaco que inhibe la proteasa del virus de la inmunodeficiencia humana (VIH) con muchas de las características de otros inhibidores de la proteasa y algunas ventajas sobre éstos, como la posología sólo una vez al día, la baja carga de comprimidos, la menor alteración gastrointestinal y un perfil metabólico más favorable, incluida la alteración del metabolismo de los hidratos de carbono. La hiperbilirrubinemia y la ictericia secundaria son su principal efecto adverso, aunque en raras ocasiones lleva a la suspensión del fármaco. Otros efectos adversos, como la nefrolitiasis o las alteraciones electrocardiográficas, son francamente raras.
Palabras clave:
Atazanavir
Perfil metabólico
Efectos adversos
Hiperbilirrubinemia
Ictericia
Atazanavir is a drug that inhibits HIV protease. It has many of the characteristics of other protease inhibitors and also some advantages over these, such as the single dose of once per day, low capsule load, less gastrointestinal problems and a very friendly metabolic profile, including carbohydrate metabolism. Secondary high plasma bilirubin and jaundice are its main adverse effect which only on rare occasions requires stopping the drug. Other adverse effects, such as nephrolithiasis or ECG changes are extremely rare.
Key words:
Atazanavir
Metabolic profile
Adverse effects
Hyperbilirubinaemia
Jaundice
Full text is only aviable in PDF
Bibliografía
[2.]
K. Squires, A. Lazzarin, J. Gatell, W.G. Powderly, V. Potrovskiy, J.F. Delfraissy, et al.
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
J Acquir Immune Defic Syndr, 36 (2004), pp. 1011-1019
[3.]
J.M. Molina, J. Andrade-Villanueva, J. Echevarría, P. Chetchotisakd, J. Corral, N. David, et al.
Once daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for managment of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Lancet, 372 (2008), pp. 646-655
[4.]
D.r. Malan, E. Krantz, N. David, V. Wirtz, J. Hammond, D. McGrath.
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
J Acquir Immune Defic Syndr, 47 (2008), pp. 161-167
[5.]
K.y. Smith, W.G. Weinberg, E. DeJesus, M.A. Fischl, Q. Liao, L.L. Ross, et al.
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
AIDS Res Ther, 28 (2008), pp. 5
[6.]
M. Johnson, B. Grinsztjn, C. Rodriguez, J. Coco, E. DeJesus, A. Lazzarin, et al.
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures.
AIDS, 20 (2006), pp. 711-718
[7.]
J. Gatell, D. Salmon-Ceron, A. Lazzarin, E. Van Wijnngaerden, F. Antunes, C. Leen, et al.
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Clin Infect Dis, 44 (2007), pp. 1484-1492
[8.]
J. Mallolas, D. Podzamczer, P. Domingo, B. Clotet, E. Ribera, F. Gutierrez, et al.
Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study.
4th Conference on HIV Pathogenesis, Treatment and Prevention,
[9.]
V. Soriano, P. Garcia-Gasco, E. Vispo, A. Ruiz-Sancho, F. Blanco, L. Martin-Carbonero, et al.
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
J Antimicrob Chemother, 61 (2008), pp. 200-205
[10.]
S. Rodriguez-Novoa, P. Barreiro, A. Rendon, A. Barrios, A. Corral, I. Jimenez-Nacher, et al.
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C->T polymorphism at the multidrug resistance gene 1.
Clin Infect Dis, 42 (2006), pp. 291-295
[11.]
B. Burchell, C. Brierley, D. Rance.
Specificity of human UDPglucuronosyltransferases and xenobiotic glucoronization.
Life Sci, 57 (1995), pp. 1819-1831
[12.]
P. Bosma, J. Chowdhury, C. Bakker, S. Gantla, A. De Boer, B. Oostra, et al.
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyl-transferase 1 in Gilbert's syndrome.
N Engl J Med, 333 (1995), pp. 1171-1175
[13.]
G. Monaghan, M. Ryan, R. Seddon, R. Hume, B. Burchell.
Genetic variation in bilirubin UPD-glucuronosyl-transferase gene promoter and Gilbert's syndrome.
Lancet, 347 (1996), pp. 578-581
[14.]
S. Rodríguez-Novoa, L. Martín-Carbonero, P. Barreiro, G. González-Pardo, I. Jiménez-Nacher, J. González-Lahoz, et al.
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
AIDS, 21 (2007), pp. 41-46
[15.]
M. Sulkowski.
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Clin Infect Dis, 38 (2004), pp. 90-97
[16.]
M.A. Noor, R.A. Parker, E. O’Mara, D.M. Grasela, A. Currie, S.L. Hodder, et al.
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
AIDS, 18 (2004), pp. 2137-2144
[17.]
M.A. Noor, O.P. Flint, J.F. Maa, R.A. Parker.
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
AIDS, 20 (2006), pp. 1813-1821
[18.]
H. Murata, P.W. Hruz, M. Mueckler.
The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
J Biol Chem, 275 (2000), pp. 20251-20254
[19.]
E. Bernal, M. Masía, S. Padilla, M. Ramos, A. Martín-Hidalgo, F. Gutiérrez.
Resistencia insulínica en pacientes con infección por el VIH en tratamiento prolongado con efavirenz, lopinavir/ritonavir y atazanavir.
Med Clin (Barc), 129 (2007), pp. 252-254
[20.]
M. Guffanti, A. Caumo, L. Galli, A. Bigoloni, A. Galli, E. Dagba, et al.
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
Eur J Endocrinol, 156 (2007), pp. 503-509
[21.]
M. Daudon, L. Estepa, J.P. Viard, D. Joly, P. Jungers.
Urinary stones in HIV- 1-positive patients treated with indinavir.
Lancet, 349 (1997), pp. 1294-1295
[22.]
S.T. Green, M.W. McKendrick, M.L. Schmid, A.H. Mohsen, S.F. Prakasam.
Renal calculi developing de novo in a patient taking saquinavir.
Int J Std AIDS, 9 (1998), pp. 555
[23.]
D.S. Engeler, H. John, K.M. Rentsch, C. Ruef, D. Oertle, S. Suter.
Nelfinavir urinary stones.
J Urol, 167 (2002), pp. 1384-1385
[24.]
T. Doco-Lecompte, A. Garrec, L. Thomas, P. Trechot, T. May, C. Rabaud.
Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases.
AIDS, 18 (2004), pp. 705-706
[25.]
J. Pacanowski, J.M. Poirier, I. Petit, J.L. Meynard, P.M. Girard.
Atazanavir urinary stones in an HIV-infected patient.
AIDS, 20 (2006), pp. 21-31
[26.]
H.R. Chang, P.M. Pella.
Atazanavir urolithiasis.
N Engl J Med, 355 (2006), pp. 2158-2159
[27.]
K.M. Chan-Tack, M.M. Truffa, K.A. Struble, D.B. Birnkrant.
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
AIDS, 21 (2007), pp. 1215-1218
[28.]
C. Couzigou, M. Daudon, J.C. Meynard, F. Borsa-Lebas, D. Higueret, L. Escaut, et al.
Urolithiasis in HIV-positive patients treated with atazanavir.
Clin Infec Dis, 45 (2007), pp. 105-108
[29.]
Bristol-Myers Squibb Company. Reyataz (atazanavir sulfate) package insert, revised February 2006. Princeton [accedido 13 Jun 2006]. Disponible en: http://www.bms.com/cgiin/anybin.pl?sql=elect+PPI+from+TB_PRODUCT_PPI+where+PPI_SEQ=103.
[30.]
Bristol-Myers Squibb Company. BMS-232632: Atazanavir briefing document May 2003. Disponible en: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibbatazanavir.pdf.
[31.]
F. Sesti, G.W. Abbott, J. Wei, et al.
A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
Proc Natl Acad Sci USA, 97 (2000), pp. 10613-10618
[32.]
B.D. Anson, J.G. Weaver, M.J. Ackerman, O. Akinsete, K. Henry, C.T. January, et al.
Blockade of HERG channels by HIV protease inhibitors.
Lancet, 365 (2005), pp. 682-686
[33.]
N. Gianottia, M. Guffantia, L. Gallia, A. Margonato, G. Chiaravallia, A. Bigolonia, et al.
Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
AIDS, 21 (2007), pp. 1648-1651
[34.]
T. Ly, M.E. Ruiz.
Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
Clin Infect Dis, 44 (2007), pp. e67-e68
[35.]
J.D. Lundgren, M. Battegay, G. Behrens, S. De Wit, G. Guaraldi, C. Katlama, et al.
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.
HIV Med, 9 (2008), pp. 72-81
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
